Independent Medical Education Grants

Independent Medical Education Grants is sponsored by Takeda Pharmaceuticals. Takeda supports high-quality, unbiased, evidence-based independent medical education for healthcare professionals, teams, patients, payers, and systems.

Independent Medical Education Grants Independent Medical Education Grants Independent Medical Education Grants # Independent Medical Education Grants Takeda and its Alliance partners are committed to supporting high-quality, un-biased, evidence-based independent medical education for healthcare professionals, teams, patients, payers and systems designed to: Improve knowledge, enhance skills, and support behavior change Close clinical and practice gaps Improve the quality and delivery of patient care Enable patients to take an active role in their healthcare Independent Medical Education is defined as education that is evidence-based, fair-balanced, unbiased, planned and implemented independent of industry influence, free of bias and not influenced by Takeda or its Alliance partners.

Takeda and its Alliance partners are committed to supporting high-quality, un-biased, evidence-based independent medical education for healthcare professionals, teams, patients, payers and systems designed to: * Improve knowledge, enhance skills, and support behavior change * Close clinical and practice gaps * Improve the quality and delivery of patient care * Enable patients to take an active role in their healthcare Independent Medical Education is defined as education that is evidence-based, fair-balanced, unbiased, planned and implemented independent of industry influence, free of bias and not influenced by Takeda or its Alliance partners.

Educational Areas of Interest ## Educational Areas of Interest Below are the independent medical education areas of interest for support by US Medical Affairs. If you have questions about an area not listed below, please contact: [email protected] Below are the independent medical education areas of interest for support by US Medical Affairs.

If you have questions about an area not listed below, please contact: [ [email protected] ](mailto: [email protected] ) ### Plaque Psoriasis (PSO) Understand the medical need/criteria for initiating plaque psoriasis patients on systemic therapy Review clinical data of next generation TYK2 inhibitors for moderate-to-severe PsO, including mechanism of action, safety, and lab monitoring Determine the role and sequencing of emerging, next generation TYK2 inhibitors in psoriasis treatment algorithms * Understand the medical need/criteria for initiating plaque psoriasis patients on systemic therapy * Review clinical data of next generation TYK2 inhibitors for moderate-to-severe PsO, including mechanism of action, safety, and lab monitoring * Determine the role and sequencing of emerging, next generation TYK2 inhibitors in psoriasis treatment algorithms Dermatology Areas in which Independent Medical Education is NOT accepting applications ### Dermatology Areas in which Independent Medical Education is NOT accepting applications Psoriatic Arthritis (PSA) * Psoriatic Arthritis (PSA) Inflammatory Bowel Disease ### Inflammatory Bowel Disease Apply best practices for early recognition and differential diagnosis of IBD based on a thorough understanding of IBD pathophysiology and disease course, including disease severity in pediatric and adult patients Determine individualized evidence-based management plans for adult and pediatric patients with IBD in accordance with treat-to-target principles, including early introduction of advanced therapies to prevent disease progression/complications and achieve long-term remission Address social drivers of health as part of culturally competent approaches to the diagnosis and management of IBD Facilitate patient-centered transitions for individuals with IBD from pediatric to adult care teams, ensuring continuity of treatment and optimizing long-term outcomes * Apply best practices for early recognition and differential diagnosis of IBD based on a thorough understanding of IBD pathophysiology and disease course, including disease severity in pediatric and adult patients * Determine individualized evidence-based management plans for adult and pediatric patients with IBD in accordance with treat-to-target principles, including early introduction of advanced therapies to prevent disease progression/complications and achieve long-term remission * Address social drivers of health as part of culturally competent approaches to the diagnosis and management of IBD * Facilitate patient-centered transitions for individuals with IBD from pediatric to adult care teams, ensuring continuity of treatment and optimizing long-term outcomes ### Eosinophilic Esophagitis Facilitate timely diagnosis and classification of EoE aligned with current guidelines and a thorough understanding of EoE pathophysiology, disease course and disease severity Optimize initial and maintenance therapy for EoE based on current safety, efficacy and real-world data for available and emerging therapies Implement best practices for personalized, evidence-based, equitable initial and ongoing management of EoE by a multidisciplinary, multispecialty team in the community setting Examine the impact of treatment delays and access issues on patient clinical outcomes and quality of life as well as healthcare costs and utilization * Facilitate timely diagnosis and classification of EoE aligned with current guidelines and a thorough understanding of EoE pathophysiology, disease course and disease severity * Optimize initial and maintenance therapy for EoE based on current safety, efficacy and real-world data for available and emerging therapies * Implement best practices for personalized, evidence-based, equitable initial and ongoing management of EoE by a multidisciplinary, multispecialty team in the community setting * Examine the impact of treatment delays and access issues on patient clinical outcomes and quality of life as well as healthcare costs and utilization Short Bowel Syndrome-Intestinal Failure (SBS-IF) ### Short Bowel Syndrome-Intestinal Failure (SBS-IF) Improve recognition of the clinical features of SBS-IF as well as quality of life impacts of the disease on pediatric and adult patients and their care partners Interpret safety, efficacy and real-world data for available and emerging therapies for children and adults with SBS-IF Apply best practices for multidisciplinary, multispecialty care of adults and children with SBS to achieve evidence-based, patient-centered and culturally competent management in the community setting * Improve recognition of the clinical features of SBS-IF as well as quality of life impacts of the disease on pediatric and adult patients and their care partners * Interpret safety, efficacy and real-world data for available and emerging therapies for children and adults with SBS-IF * Apply best practices for multidisciplinary, multispecialty care of adults and children with SBS to achieve evidence-based, patient-centered and culturally competent management in the community setting Gastroenterology Areas in which Independent Medical Education is NOT accepting applications ### Gastroenterology Areas in which Independent Medical Education is NOT accepting applications Irritable Bowel Syndrome (IBS) Chronic Idiopathic Constipation (CIC) Crohn’s Perianal Fistulas (CPF) Fellowships except in response to a specific Call for Grant Applications (CGA).

CGA postings can be found by following this link: https://tsupportportal. com/CGA/index. html * Irritable Bowel Syndrome (IBS) * Chronic Idiopathic Constipation (CIC) * Crohn’s Perianal Fistulas (CPF) * Fellowships except in response to a specific Call for Grant Applications (CGA).

CGA postings can be found by following this link: [https://tsupportportal. com/CGA/index. html](https://tsupportportal.

com/CGA/index.

html) Facilitate personalized management plans based on available clinical data and real-world evidence for patients with hemophilia A including previously untreated patients, minimally treated patients, and those receiving non-factor therapy prophylaxis Recognize the role of FVIII and the importance of preventing inhibitor development in patients with hemophilia A * Facilitate personalized management plans based on available clinical data and real-world evidence for patients with hemophilia A including previously untreated patients, minimally treated patients, and those receiving non-factor therapy prophylaxis * Recognize the role of FVIII and the importance of preventing inhibitor development in patients with hemophilia A Von Willebrand Disease (VWD) ### Von Willebrand Disease (VWD) Apply a fundamental understanding of VWD pathophysiology in making individualized treatment decisions for adult and pediatric patients with VWD, including the interplay between FVIII and VWF, the role of multimers, and exposure to ADAMTS13 Review the importance of multimeric profile in the treatment of VWD Use clinical and real-world evidence to formulate appropriate personalized on-demand and prophylactic treatment plans for adult and pediatric patients with VWD in accordance with disease severity Optimize management of bleeding events such as epistaxis, heavy menstrual bleeding, post-partum hemorrhage, and gastrointestinal bleeding in pediatric and adult patients with VWD * Apply a fundamental understanding of VWD pathophysiology in making individualized treatment decisions for adult and pediatric patients with VWD, including the interplay between FVIII and VWF, the role of multimers, and exposure to ADAMTS13 * Review the importance of multimeric profile in the treatment of VWD * Use clinical and real-world evidence to formulate appropriate personalized on-demand and prophylactic treatment plans for adult and pediatric patients with VWD in accordance with disease severity * Optimize management of bleeding events such as epistaxis, heavy menstrual bleeding, post-partum hemorrhage, and gastrointestinal bleeding in pediatric and adult patients with VWD Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) ### Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Reduce healthcare disparities in CIDP by addressing knowledge gaps among healthcare professionals through education on the patient journey, guidelines-based diagnosis, differential diagnosis, and treatment options Improve adherence to evidence-based treatment guidelines for induction and maintenance therapy with immunoglobulin (Ig) therapies in CIDP Enhance the understanding of Ig mechanism of action and equip clinicians with practical skills to evaluate Ig safety, efficacy, and administration * Reduce healthcare disparities in CIDP by addressing knowledge gaps among healthcare professionals through education on the patient journey, guidelines-based diagnosis, differential diagnosis, and treatment options * Improve adherence to evidence-based treatment guidelines for induction and maintenance therapy with immunoglobulin (Ig) therapies in CIDP * Enhance the understanding of Ig mechanism of action and equip clinicians with practical skills to evaluate Ig safety, efficacy, and administration Hereditary Angioedema (HAE) ### Hereditary Angioedema (HAE) Review evidence-based, guideline-concordant diagnosis and management strategies for patients with HAE including HAE-nl-C1INH angioedema Explore the importance of personalized management of HAE, encompassing treatment and prophylaxis for patients across the lifecycle Examine the impact of social drivers of health (SDOH) on HAE disease management and patient outcomes to overcome disparities of care among patient groups * Review evidence-based, guideline-concordant diagnosis and management strategies for patients with HAE including HAE-nl-C1INH angioedema * Explore the importance of personalized management of HAE, encompassing treatment and prophylaxis for patients across the lifecycle * Examine the impact of social drivers of health (SDOH) on HAE disease management and patient outcomes to overcome disparities of care among patient groups Primary Immunodeficiency Disease (PID) ### Primary Immunodeficiency Disease (PID) Improve time to diagnosis, diagnostic workup, and recognition of clinical signs suggestive of PID Review the impact of and exploring strategies to optimize treatment adherence across parenteral immunoglobulin modalities, including infusion burden, patient preference Examine health disparities experienced by PID patients, including impact of race and ethnicity on disease management and challenges faced by patients living in rural areas Promote patient-centered approaches to care and shared decision-making supporting patient understanding of treatment options and addressing care transition from pediatric to adult * Improve time to diagnosis, diagnostic workup, and recognition of clinical signs suggestive of PID * Review the impact of and exploring strategies to optimize treatment adherence across parenteral immunoglobulin modalities, including infusion burden, patient preference * Examine health disparities experienced by PID patients, including impact of race and ethnicity on disease management and challenges faced by patients living in rural areas * Promote patient-centered approaches to care and shared decision-making supporting patient understanding of treatment options and addressing care transition from pediatric to adult Immunology Areas in which Independent Medical Education is NOT accepting applications ### Immunology Areas in which Independent Medical Education is NOT accepting applications Alpha-1 Antitrypsin Deficiency (AATD) focused on lung disease Immune-mediated inflammatory conditions other than CIDP and PID Multifocal motor neuropathy or neuromuscular disorders other than CIDP Secondary immunodeficiency disorders Systemic Lupus Erythematosus (SLE) * Alpha-1 Antitrypsin Deficiency (AATD) focused on lung disease * Immune-mediated inflammatory conditions other than CIDP and PID * Multifocal motor neuropathy or neuromuscular disorders other than CIDP * Secondary immunodeficiency disorders * Systemic Lupus Erythematosus (SLE) ### Narcolepsy Type 1 (NT1) Explore the burden of illness of individuals with narcolepsy including effects on cognition, mental health, and quality of life Appraise and address factors contributing to prolonged diagnosis from the perspectives of multi-specialty clinicians, patients and healthcare system challenges Find ways to improve diagnosis rates by optimizing clinical interviews, diagnostic testing methods, and the ability to differentiate NT1 from other sleep disorders, comorbid mental health and other conditions and medication effects Elucidate the role of orexin in sleep-wake regulation and pathophysiology of narcolepsy Understand and assess the clinical evidence and mechanism of action of new treatments for NT1, including orexin receptor 2 agonists * Explore the burden of illness of individuals with narcolepsy including effects on cognition, mental health, and quality of life * Appraise and address factors contributing to prolonged diagnosis from the perspectives of multi-specialty clinicians, patients and healthcare system challenges * Find ways to improve diagnosis rates by optimizing clinical interviews, diagnostic testing methods, and the ability to differentiate NT1 from other sleep disorders, comorbid mental health and other conditions and medication effects * Elucidate the role of orexin in sleep-wake regulation and pathophysiology of narcolepsy * Understand and assess the clinical evidence and mechanism of action of new treatments for NT1, including orexin receptor 2 agonists Neuroscience Areas in which Independent Medical Education is NOT accepting applications ### Neuroscience Areas in which Independent Medical Education is NOT accepting applications Attention-deficit/hyperactivity disorder Central Disorders of Hypersomnolence other than NT1 Developmental and Epileptic Encephalopathy, Adult Epilepsy, or Pediatric Epilepsy Major Depressive Disorder (MDD) * Attention-deficit/hyperactivity disorder * Central Disorders of Hypersomnolence other than NT1 * Developmental and Epileptic Encephalopathy, Adult Epilepsy, or Pediatric Epilepsy * Major Depressive Disorder (MDD) Emphasize the importance of newborn screening initiatives and biomarkers to enable early diagnosis Evaluate the safety and efficacy of available treatments Address challenges in Women’s Health in Gaucher Disease and strategies to support personalized care Identifying the drivers of bone disease in Gaucher patients and its impact on treatment outcomes * Emphasize the importance of newborn screening initiatives and biomarkers to enable early diagnosis * Evaluate the safety and efficacy of available treatments * Address challenges in Women’s Health in Gaucher Disease and strategies to support personalized care * Identifying the drivers of bone disease in Gaucher patients and its impact on treatment outcomes Hunter Syndrome (Mucopolysaccharidosis II, MPS II) ### Hunter Syndrome (Mucopolysaccharidosis II, MPS II) Improve patient outcomes through newborn screening and strategies to support implementation of NBS Optimize disease management strategies to support personalized care for individuals Identify the challenges faced by patients with Hunter Syndrome and their caregivers * Improve patient outcomes through newborn screening and strategies to support implementation of NBS * Optimize disease management strategies to support personalized care for individuals * Identify the challenges faced by patients with Hunter Syndrome and their caregivers Rare Metabolic Diseases Areas in which Independent Medical Education is NOT accepting applications ### Rare Metabolic Diseases Areas in which Independent Medical Education is NOT accepting applications Metachromatic Leukodystrophy (MLD) * Metachromatic Leukodystrophy (MLD) Transplant/Cytomegalovirus Infection (CMVi) ### Transplant/Cytomegalovirus Infection (CMVi) Recognize the burden of illness and unmet needs of inadequately treated CMVi among transplant recipients Identify risk factors and mitigation strategies for CMVi reactivation and inadequately CMVi Highlight the importance of early identification and monitoring of high-risk post-transplant patients for timeline treatment intervention/s Address challenges in managing tolerability or adverse effects of anti-viral treatments for CMVi Identify barriers and unmet treatment needs for post-transplant recipients with CMVi, including treatment intolerance and inadequately treated, refractory or drug-resistant CMVi Evaluate safety, efficacy and impact of modern treatment strategies for CMVi * Recognize the burden of illness and unmet needs of inadequately treated CMVi among transplant recipients * Identify risk factors and mitigation strategies for CMVi reactivation and inadequately CMVi * Highlight the importance of early identification and monitoring of high-risk post-transplant patients for timeline treatment intervention/s * Address challenges in managing tolerability or adverse effects of anti-viral treatments for CMVi * Identify barriers and unmet treatment needs for post-transplant recipients with CMVi, including treatment intolerance and inadequately treated, refractory or drug-resistant CMVi * Evaluate safety, efficacy and impact of modern treatment strategies for CMVi Vaccine Areas in which Independent Medical Education is NOT accepting applications ### Vaccine Areas in which Independent Medical Education is NOT accepting applications Please visit Takeda Support for additional information on submitting medical education grant requests.

If you have any questions regarding Takeda’s medical education grants, please contact [email protected] . Please visit [Takeda Support](http://www. tsupportportal.

com/) for additional information on submitting medical education grant requests. If you have any questions regarding Takeda’s medical education grants, please contact [ [email protected] ](mailto: [email protected] ).